What have we learned in dermatology from the biologic therapies? - 09/08/11
, Seth R. Stevens, MD b
Correspondence to: Brian J. Nickoloff, MD, PhD, Skin Disease Research Laboratory, Cardinal Bernardin Cancer Center, Loyola University of Chicago, 2160 S First Ave, Bldg 112, Room 301, Maywood, IL 60153.Maywood, Illinois, and Thousand Oaks, California
Abstract |
Recent advances in our basic understanding of immunology, specifically the roles of various cell types involved in immune response and the action of cytokines they produce, has radically changed our understanding of the origin of inflammatory dermatoses, and other autoimmune diseases. Broadened comprehension of the immune response on a molecular level has facilitated the development of biologic therapeutics for the treatment of psoriasis, atopic dermatosis, and other inflammatory conditions. However, despite major advances in development and use of targeted biologics for controlling autoimmune disease, effective cures for these conditions remain to be developed and genetic determinants of predisposition to such diseases remain to be identified. Here, we review the history of our understanding of inflammatory dermatoses, traditional and new treatment approaches, and future directions for research and therapy in this area.
Le texte complet de cet article est disponible en PDF.Abbreviations used : Ab, AD, APC, DC, IFN, Ig, IL, LFA, mAb, NK, PsO, TH1, TH2, TNF
Plan
| Supported by Amgen Inc and Wyeth Research. Dr Nickoloff has received an honorarium for this article. He has served as a speaker in Amgen-sponsored CME symposia. Dr Stevens is an employee of and has been granted stock and stock options in Amgen Inc. Reprints not available from the authors. |
Vol 54 - N° 3S2
P. S143-S151 - mars 2006 Retour au numéro
Article précédent
- Case reports of etanercept in inflammatory dermatoses
- Robert Norman, Robert G. Greenberg, J. Mark Jackson
- Treatment of necrobiosis lipoidica with the tumor necrosis factor antagonist etanercept
- Joshua A. Zeichner, Dana W.K. Stern, Mark Lebwohl
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?